報價延遲最少15分鐘:2024/11/16 09:03 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
15.25 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.77/0.06
|
|
企業價值
1.56B
|
| 資產負債 |
|
每股賬面淨值
8.15
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
753.20M
|
|
每股收益
8.09
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/11/16 09:03 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarkerdiscovery and companion diagnostic services to pharma and biotech companies. |